Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (9)

2024

  1. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

    eBioMedicine, Vol. 102

2023

  1. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma

    Nature Communications, Vol. 14, Núm. 1

  2. Abrogation of stemness in osteosarcoma by the mithramycin analog EC-8042 is mediated by its ability to inhibit NOTCH-1 signaling

    Biomedicine and Pharmacotherapy, Vol. 162

  3. Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma

    Redox Biology, Vol. 62

  4. Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells

    Free Radical Biology and Medicine, Vol. 209, pp. 127-134

  5. Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer

    Biomedicines, Vol. 11, Núm. 1

2022

  1. Addressing Doxorubicin Resistance in Bone Sarcomas using Novel Drug‐Resistant Models

    International Journal of Molecular Sciences, Vol. 23, Núm. 12

2019

  1. Pyruvate Plays a Main Role in the Antitumoral Selectivity of Cold Atmospheric Plasma in Osteosarcoma

    Scientific Reports, Vol. 9, Núm. 1

  2. Sarcoma Stem Cell Heterogeneity

    Advances in Experimental Medicine and Biology (Springer New York LLC), pp. 95-118